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Background/aim: Visfatin has been reported to be closely related to cardiovascular diseases associated with inflammation, but the
correlation between visfatin and ventricular arrhythmia (VA) has not been discussed yet. The study aims to explore the association
between serum visfatin concentrations and VA in patients.
Materials and methods: Sixty-seven hospitalized patients diagnosed with VA and 131 control subjects were enrolled in this crosssectional study between May 20, 2017 and November 8, 2019. Classification of VA types was based on the presence of structural heart
disease (SHD). The patients’ blood samples were collected to examine their serum levels of visfatin. Results were analyzed using analysis
of variance and t-test. Furthermore, binary logistic regression analysis was used to validate whether elevated visfatin was independently
associated with VA.
Results: Compared with the controls (mean age, 64.2 ± 13.2 years; 71% of men), the patients with VA (68.2 ± 11.6 years, 58%) had
higher serum levels of visfatin (1.80 ± 0.47 ng/mL versus 1.48 ± 0.41 ng/mL; p <0.001). After further grouping patients according to the
presence of SHD, the serum levels of VA patients with SHD were the highest. Moreover, binary logistic regression analysis identified
age (OR = 1.043; 95% CI, 1.015–1.072, p = 0.003), history of stroke (OR = 2.065; 95% CI, 1.450–5.696, p = 0.005), hsCRP (>10 mg/L)
(OR = 4.123; 95% CI, 1.888–9.001, p < 0.001), and elevated visfatin level (>1.40 ng/L) (OR = 3.126; 95% CI, 1.544–6.328, p = 0.002) as
independent risk factors with VA.
Conclusion: Serum visfatin levels were significantly elevated in the patients with VA, and increased with the risk rating of VA.
Key words: Visfatin, ventricular arrhythmia, structural heart disease, biomarkers

1. Introduction
In recent years, cardiac arrhythmias have become lifethreatening complications of heart diseases and have
shown an increased prevalence in the general population
[1, 2]. Although medical equipment and technologies have
developed rapidly for centuries, the effective treatments
for sinus rhythm restoration in patients with ventricular
arrhythmias (VA) are radiofrequency ablation and
antiarrhythmic drugs. Due to its complex etiology and
mechanism [3], predicting life-threatening VA remains
challenging. With the steady increase in its incidence, new
and efficacious indicators are urgently needed to predict
the occurrence of VA in clinical practice.
Owing to the essential role of the inflammatory
responses of adipocytokines in various cardiovascular
diseases and metabolic disorders, the predictive values
of biomarkers, such as visfatin, have been extensively

studied and validated [4]. Visfatin (known as a pre-B cell
cloning enhancer [5, 6]) is secreted by visceral fat, which
exerts insulin-mimetic effects and is closely related to
metabolic disorders [7]. Moreover, considering its strong
inflammatory effects, visfatin has provided reliable evidence
regarding prediction of the prevalence of cardiovascular
diseases [8-10], and the findings of previous studies have
suggested that acute coronary syndromes increase the
incidence of VA [11, 12]. Furthermore, epicardial fat
thickness has been reported to be significantly correlated
with the concentrations of visfatin [13], and increased
epicardial fat thickness was observed in patients with
frequent ventricular premature beats [14]. However, the
correlation between serum visfatin levels and VA has not
yet been discussed and involved. Thus, the purpose of this
study is to explore the relationship between serum visfatin
concentrations and VA in patients.
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2. Materials and methods
2.1. Study population
The aim of this cross-sectional study was to explore the
association between serum visfatin levels and VA in
patients. Sixty-seven patients with VA and 131 control
subjects, both matched for age and sex, who were recruited
from the outpatient clinic of Department of Cardiology,
Shanghai Tenth People’s Hospital (China), were enrolled
in this study between May 20, 2017 and November 8,
2019. This study was approved by the ethics committee of
Shanghai Tenth Hospital, and written informed consent
was obtained from all participants. Of the 198 patients
(55% male; mean age, 65.57 ± 12.81 years) included in this
study, 24 (12%) and 10 (5%) patients reported smoking and
alcohol consumption habits, respectively. Hypertension
and diabetes mellitus were respectively diagnosed in 64%
and 18% of the patients, and 11% had hyperlipidemia.
Additionally, 21% of the patients had a history of stroke.
The inclusion criteria were as follows: (1) age ≥18
years; (2) no liver or kidney injury, hematologic diseases,
tumors, inflammation, or immune system diseases.
Regarding the diagnostic and grouping standards used for
VA, VA was diagnosed using routine electrocardiogram
and 24-h Holter monitoring and confirmed by further
electrophysiological examination. Of the patients with
VA, 33 (49%) had premature ventricular beats, 28 (42%)
had ventricular tachycardia, and 6 (9%) had ventricular
fibrillation.
Structural heart disease (SHD) was defined as previous
diagnosis of ischemic heart disease, heart failure, valve
dysfunction (mild valve regurgitation was not included
in this group), or primary myocardial structural disease
[15], and 51% of patients with SHD were enrolled in
the clinical research. The disease distribution of SHD in
patients without ventricular arrhythmias was as follows: 4
cases of dilated cardiomyopathy, 13 cases of valvulopathy,
31 cases diagnosed with coronary heart disease, 11 cases
with heart failure, and 7 cases of rheumatic myocarditis.
The disease distribution of SHD in patients with
ventricular arrhythmias was as follows: 10 cases of dilated
cardiomyopathy, 5 cases of hypertrophic cardiomyopathy,
4 cases of arrhythmic right ventricular cardiomyopathy,
and 15 cases diagnosed with coronary heart disease.
2.2. Risk factor analysis and laboratory assessments
All subjects provided detailed information, including
demographic data, results of serological tests, and medical
histories. Smokers included current and former smokers.
Patients’ body-mass index (BMI) was calculated by
measuring their height and weight. Blood pressure was
measured after the patient was instructed to sit for at
least 10 min. The measurement was then taken twice on
the right arm using a mercury sphygmomanometer. The
mean systolic and diastolic values of the same sample
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were measured twice in succession. The left ventricular
ejection fraction (LVEF) of each patient was assessed using
echocardiography.
Blood samples were collected after overnight fasting
and centrifuged at 1000 × g for 10 min, and the serum
samples were frozen at −80 °C for biochemical analysis.
Serum levels of visfatin were determined using a human
visfatin enzyme-linked immunosorbent assay (ELISA) kit
(SAB, Maryland, USA) according to the manufacturer’s
instructions. The detection range of the ELISA kit was
0.156–10 ng/mL, and the assay sensitivity was 0.059 ng/
mL.
Indexes of inflammation and metabolism, including
lipid profiles (total cholesterol [TC], triglyceride [TG],
high-density lipoprotein cholesterol [HDL-C], and lowdensity lipoprotein cholesterol [LDL-C]), white blood
cell count (WBC), and high-sensitivity C-reactive protein
(hsCRP)), were measured using colorimetric enzymatic
assay systems (Roche MODULAR P-800, Switzerland).
Blood samples, routine electrocardiogram/24-h Holter
monitoring and echocardiography were all measured
immediately after patients were enrolled in the study.
2.3. Statistical analysis
Continuous variables such as demographic and clinical
characteristics were expressed as mean ± standard
deviation (SD). Categorical variables were presented
as frequency and assessed with chi-squared test.
Comparisons of continuous variables between different
groups were assessed using the two-tailed unpaired t-test,
and comparisons between groups were performed by
with chi-squared test. The assessment of correlations of
visfatin with clinical and biomedical indicators was done
using the Spearman correlation coefficient. The predictive
value of visfatin concentration was tested using the area
under the receiver operator characteristic (ROC) curve.
Serum concentrations of visfatin were grouped using the
largest Youden index that corresponds to the cut-off value
of 1.40 ng/mL. Subsequently, we adopted binary logistic
regression analysis to evaluate VA/control binomial
variables and other related variables including elevated
serum visfatin level (>1.40 ng/L), using the odds ratio
(OR), and 95% confidence interval (CI) of the maximum
likelihood parameter estimates. All data were analyzed
by SPSS 22.0 for Windows (SPSS Inc., Chicago, IL), and a
bilateral probability level <0.05 was considered statistically
significant.
3. Results
3.1. Participant characteristics
A total of 198 subjects, including 131 control and 67
patients with VA, were included in the final analysis (Figure
1). The basic characteristics of the participants are shown
in Table 1. The control subjects and the patients with VA
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Exclusion criteria:
1.Age < 18 years
2.Patients with liver or kidney
injury, hematologic diseases,
tumors, inflammation, or
immune system diseases

198 patients were enrolled
ventricular arrhythmias(VA) on admission

Control group
(n=131)

VA group
(n=67)

Structural heart disease
(SHD) on admission

Control without
SHD group(n=65)

Control with SHD
group(n=66)

Structural heart disease
(SHD) on admission

VA without SHD
group(n=33)

VA with SHD
group(n=34)

Figure 1. Diagram of study participants.

did not differ significantly with respect to age, male sex,
BMI, smoking, alcohol consumption, WBC count, LVEF%
and other conventional cardiovascular risk factors such as
hypertension, diabetes, hyperlipidemia, and structural heart
disease. The VA group had higher proportion of patients
with history of stroke (28% versus 17%; p = 0.045) than the
control subjects. Furthermore, higher hsCRP concentrations
(4.61 ± 3.21 mg/L versus 3.53 ± 2.53 mg/L; p = 0.010), and
a higher proportion of patients with hsCRP over 10 mg/L
(34% versus 16%; p = 0.006) were observed in the VA group.
We divided the patients with VA into non-SHD (also
known as benign VA) and SHD subgroups (also defined
as malignant VA)[16] based on the presence of SHD, and
control patients were also grouped in the same way for
subsequent comparison. The demographic characteristics
of the four groups were presented in Table 2. In control
patients without VA, SHD subgroup had higher BMI
index than non-SHD subjects (25.3 ± 2.4 versus 24.0 ± 2.4;
p = 0.016). Compared to non-SHD subgroups, patients
in both the control (46% versus76%; p = 0.002) and VA
groups (52% versus 85%; p = 0.015) had higher proportion
of hypertension in the SHD subgroups. No statistical
differences were noted after the analysis of other variables.
3.2. Correlations between visfatin and other factors
When serum visfatin concentrations were analyzed, we
found that patients with VA had higher visfatin levels
(1.80 ± 0.47 ng/mL versus 1.48 ± 0.41 ng/mL; p < 0.001;
Table 1) than the control group. After adjustment for VA
and SHD, the serum levels of VA patients with SHD were
the highest, followed by control with SHD and VA without
SHD subgroup, and control without SHD subgroup was
the lowest (Figure 2). The visfatin serum concentrations
of both non-SHD (1.60 ± 0.46 vs. 1.34 ± 0.04 ng/mL,
p<0.001) and SHD patients (1.98 ± 0.07 vs. 1.63 ± 0.40

ng/mL, p < 0.001) were significantly elevated in the VA
subgroup. Meanwhile, the mean serum level of visfatin in
the SHD subgroup was higher than that in the non-SHD
group regardless of the presence of VA (control group, 1.63
± 0.40 vs. 1.34 ± 0.04 ng/mL, p < 0.001; VA group, 1.98 ±
0.07 vs. 1.60 ± 0.46 ng/mL, p < 0.001). Of note, it showed
significant differences between serum concentrations of
visfatin and some elements like BMI (r = 0.321, p < 0.001),
hyperlipidemia (r = 0.158, p = 0.026), VA (r = 0.316, p <
0.001) and SHD (r = 0.145, p = 0.042) as Table 3.
Binary logistic regression analysis was applied to all
data and the results are shown in Table 4. With ventricular
arrhythmia as the dependent variable, and age, history
of stroke, hsCRP (>10 mg/L), and elevated visfatin level
(>1.40ng/L) as independent variables by univariate
analyses shown in Table 1, the results revealed a significant
positive association between the occurrence of ventricular
arrhythmia and age (OR = 1.043; 95% CI, 1.015–1.072, p =
0.003), history of stroke (OR = 2.065; 95% CI, 1.450–5.696,
p = 0.005), hsCRP (>10 mg/L) (OR = 4.123; 95% CI, 1.888–
9.001, p < 0.001), and elevated visfatin level (>1.40 ng/L)
(OR = 3.126; 95% CI, 1.544–6.328, p = 0.002) (Table 4). A
visfatin level equal to 1.40 ng/mL had a sensitivity of 51% and
a specificity of 79% for the prediction of VA by ROC curve,
and was defined as a cut-off value for the evaluation of the
predictive value for the occurrence of VA. The area under
the ROC curve for the visfatin to predict any type of VA
was 0.693 (Figure 3a), the positive and negative predictive
values were respectively 55.7% and 75.9%; for predicting
VA without SHD (benign VA) was 0.6059 (Figure 3b), the
positive and negative predictive values were respectively
57.6% and 51.5%; and for VA with SHD (malignant VA)
was 0.8028 (Figure 3c), the positive and negative predictive
values were 94.1% and 79.6%, respectively.
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Table 1. Baseline characteristics of the cohort subjects.

Parameter

Controls
(n = 131)

VA group
(n = 67)

P value

Age, years

64.2 ± 13.2

68.2 ± 11.6

0.077

Male, n (%)

54 (71)

60 (58)

0.651

BMI (kg/m )

24.6 ± 2.3

25.2 ± 3.3

0.152

Smoking, n (%)

14 (11)

10 (15)

0.368

Alcohol consumption, n (%)

7 (5)

3 (4)

0.999

Diabetes, n (%)

25 (19)

10 (15)

0.557

Hypertension, n (%)

80 (61)

46 (61)

0.350

SBP, mmHg

139.6 ± 23.9

138.7 ± 18.6

0.774

DBP, mmHg

77.6 ± 14.1

75.1 ± 14.3

0.228

Hyperlipidemia, n (%)

17 (13)

4 (6)

0.150

TC, mmol

4.3 ± 1.1

4.5 ± 1.7

0.2213

TG, mmol/L

1.8 ± 1.2

1.7 ± 0.7

0.4020

HDL-C, mmol/L

1.2 ± 0.3

1.2 ± 0.3

0.8356

LDL-C, mmol/L

2.7 ± 0.9

2.5 ± 0.7

0.2152

History of stroke, n (%)

22 (17)

19 (28)

0.045*

SHD, n (%)

66 (50)

34 (51)

0.999

WBC, ×109/L

6.4 ± 2.2

6.0 ± 1.8

0.209

hsCRP, mg/L

3.5 ± 2.5

4.6 ± 3.2

0.010*

hsCRP (>10mg/L)

21 (16)

23 (34)

0.006**

LVEF, %

60.7 ± 9.8

58.8 ± 11.2

0.218

Class I antiarrhythmic drugs

/

2 (3)

β-blocker

40 (31)

46 (69)

Amiodarone

/

20 (30)

Visfatin, ng/mL

1.48 ± 0.41

1.80 ± 0.47

<0.001**

68 (52)

49 (73)

0.006**

2

Medication

a

Elevated visfatin level

<0.001**

Continuous variables are shown as mean ± SD; categorical variables are presented as frequency counts (proportion). BMI,
body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; n, number of patients; TC, total cholesterol; TG,
triglycerides; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; SHD, structural heart
disease; WBC, white blood cell count; hsCRP, high-sensitivity C-reactive protein; LVEF, left ventricular ejection fraction.
* indicates statistically significant p-values; *p < 0.05, **< 0.01 (analyzed using the two-tailed unpaired t-test or chi-squared
test).
a
Elevated visfatin level: visfatin concentration over 1.40 ng/mL.

4. Discussion
In this study, we investigated the association between
baseline serum visfatin concentration and the occurrence
and risk stratification of VA. VA is always acknowledged
as a main complication of heart diseases and is one of
the hotspots and challenges in cardiac research. Previous
studies have shown that different risk factors lead to the
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occurrence of VA. However, there is no single effective
index for the clinical prediction of VA to date [17].
To our knowledge, the present study is the first to
reveal that the serum visfatin levels of patients with VA
are significantly elevated, and the increase persisted after
SHD adjustment. After binary logistic analysis, we identify
elevated visfatin concentrations (>1.40 ng/mL), age,
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Table 2. Comparison of baseline characteristics of the patients with ventricular arrhythmias after adjustment for the presence of
structural heart disease.
Control group

VA group

Parameter

Non-SHD (n = 65)

SHD (n = 66)

p-value

Non-SHD (n = 33)

SHD (n = 34)

p-value

Age, years

62.7 ± 14.5

65.8 ± 11.7

0.180

65.8 ± 10.0

70.5 ± 12.7

0.098

Male, n (%)

32 (49)

37 (56)

0.486

20 (61)

19 (56)

0.806

BMI (kg/m )

24.0 ± 2.4

25.3 ± 2.4

0.002**

24.4 ± 2.9

26.1 ± 2.9

0.019*

Smoking, n (%)

3(5)

11 (17)

0.045*

2 (9)

8 (21)

0.083

Alcohol, n (%)

2(3)

5 (8)

0.440

2 (6)

1 (3)

0.614

Diabetes, n (%)

7 (11)

18 (27)

0.025*

1 (3)

9 (26)

0.013*

Hypertension, n (%)

30 (46)

50 (76)

0.001**

17 (52)

29 (85)

0.004**

Hyperlipidemia, n (%)

2

7 (11)

10 (15)

0.604

2 (6)

2 (6)

0.999

History of stroke, n (%) 8 (12)

15 (23)

0.168

8 (24)

11 (32)

0.590

WBC, ×10 /L

6.0 ± 1.9

6.7 ± 2.4

0.067

5.9 ± 1.1

6.0 ± 2.3

0.825

hsCRP, mg/L

4.1 ± 5.1

5.1 ± 6.6

0.334

4.2 ± 2.3

5.0 ± 3.8

0.303

hsCRP (>10 mg/L)

9 (14)

12 (18)

0.635

10 (30)

13 (38)

0.609

LVEF, %

62.8 ± 11.4

58.5 ± 8.1

0.022*

63.1 ± 4.3

56.4 ± 13.0

0.007**

Class I drugs

/

/

0 (0)

2 (6)

0.493

β-blocker

/

40(60)

20 (61)

26 (76)

0.194

Amiodarone

/

/

8 (24)

11 (32)

0.590

9

Continuous variables are shown as mean ± SD; categorical variables are presented as frequency counts (proportion). SHD,
structural heart disease; LVEF, left ventricular ejection fraction; WBC, white blood cell count; hsCRP, high-sensitivity C-reactive
protein. Class I drugs, Class I antiarrhythmic drugs.
* indicates statistically significant p-values; *p < 0.05, **p < 0.01 (analyzed using the two-tailed unpaired t-test or chi-squared test).
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Figure 2. Serum visfatin levels of the participants in the study groups.After grouping by structural heart disease (SHD) and ventricular
arrhythmias (VA), the serum levels of VA patients with SHD were the highest, followed by control with SHD and VA without SHD
subgroup, and control without SHD subgroup was the lowest. When the study population was grouped according to SHD absence/
presence, the concentration of visfatin in VA group was significantly higher than that in control group (VA without SHD vs. control
without SHD, 1.60 ± 0.46 vs. 1.34 ± 0.04 ng/mL, p < 0.001; VA with SHD vs. control with SHD, 1.98 ± 0.07 vs. 1.63 ± 0.40 ng/mL, p <
0.001). Meanwhile, when the study population was grouped according to VA absence/presence, the concentration of visfatin in SHD
group was significantly higher than that in non-SHD group (control with SHD vs. control without SHD, 1.63 ± 0.40 vs. 1.34 ± 0.04 ng/
mL, p < 0.001;VA with SHD vs. VA without SHD, 1.98 ± 0.07 vs. 1.60 ± 0.46 ng/mL, p < 0.001).
* indicates statistically significant p-values; **p < 0.01. All data were presented as mean ± SD, and analyzed with the two-tailed unpaired
t-test.
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Specificity%
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0
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Figure 3. Association between serum visfatin concentrations and the occurrence of VA and ROC
curves. Construction of receiver operating characteristic (ROC) curves confirmed that serum
visfatin concentrations significantly differentiated VA (a), benign VA (VA without SHD, b),
malignant VA (VA with SHD, c). SHD: structural heart disease.

Table 3. Correlations between visfatin and other elements.
Parameter

r

p-value

Age, years

–0.022

0.760

Male, n (%)

0.075

0.295

BMI (kg/m2)

0.321

<0.001**

Smoking, n (%)

0.057

0.423

Alcohol consumption, n (%)

0.046

0.518

Diabetes, n (%)

0.068

0.341

Hypertension, n (%)

0.085

0.236

Hyperlipidemia, n (%)

0.158

0.026*

History of stroke, n (%)

0.073

0.307

WBC, ×10 /L

0.047

0.510

hsCRP, mg/L

0.036

0.632

LVEF, %

–0.035

0.642

VA

0.316

<0.001**

SHD

0.145

0.042*

9

r was presented as Spearman correlation coefficient. WBC, white blood cell count;
hsCRP, high-sensitivity C-reactive protein; LVEF, left ventricular ejection fraction; VA,
ventricular arrhythmia; SHD, structural heart disease. * indicates statistically significant
p-values; *p < 0.05, **< 0.01 (analyzed using correlation analysis of binary variables).
Table 4. Results of binary regression logistic analysis for factors correlated with ventricular arrhythmias.
Factors
All subjects (n = 198)

OR

95% CI

p-value

Age

1.043

1.015–1.072

0.003**

History of stroke

2.065

1.450–5.696

0.005**

hsCRP (>10mg/L)

4.123

1.888–9.001

<0.001**

3.126

1.544–6.328

0.002**

a

Elevated visfatin level

OR, odds ratio; CI, confidence interval;
* indicates statistically significant p-values; *p < 0.05, **<0.01;
a
Elevated visfatin level: visfatin concentration over 1.40 ng/mL.
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history of stroke, and hsCRP (>10 mg/L) as independent
risk factors for the presence of VA. Compared to the VA
patients without SHD (benign VA), the serum level of
visfatin is significantly higher in VA with SHD subgroup
(malignant VA). These results indicate that the serum level
of visfatin is not only related to the occurrence of VA but
can also predict its risk stratification.
Although the coexistence of VA with atherosclerotic
plaques and inflammatory processes has been gradually
studied, the exact mechanism behind VA remains elusive.
VA frequently occurs in patients with inflammatory diseases,
such as inflammatory bowel disease [18], rheumatoid
arthritis [19], and psoriasis [20]. Stefania et al. has
previously reported that the inflammatory activities of the
left stellate ganglion is increased in patients with malignant
VA [21], which suggests that increased inflammation may
increase the incidence of VA. Furthermore, in patients
along with old myocardial infarction, cardiac enlargement,
and low LVEF, atherosclerotic plaque progression leading
to ischemia is always the cause of cardiac arrhythmias.
Therefore, more research on the role of atherosclerotic
plaques and inflammatory biomarkers, such as hsCRP, has
been designed to predict VA. Furthermore, the predictive
value of malignant VA in non-ST elevation myocardial
infarction has been reported [22].
Visfatin is a well-explored adipocytokine secreted
mainly by visceral adipose tissue, and a new cytokine
that regulates the expression of inflammatory factors
in leukocytes [23, 24]. Visfatin was demonstrated to
be a new mediator released by human endothelial cells
in inflammatory conditions [25]. Additionally, visfatin
promotes angiogenesis of endothelial cells and local
progressive neovascularization in atheromatous plaques
and significantly increases plaque instability [26]. Visfatin
mRNA has been previously reported to upregulate in
chronic inflammatory diseases, including atherosclerosis
and inflammatory bowel disease [27]. Therefore, elevated
visfatin levels indicate the progression of atherosclerotic
plaques and increased inflammatory responses, both of
which play essential roles in the induction of VA.
In the present study, serum visfatin concentrations of
the patients with VA in the SHD subgroup are significantly
elevated compared with those of patients with benign
VA. A plausible reason behind this finding is that patients
with SHD have more cardiac structural changes and
increased hemodynamic disorders, and the control group
also confirms the conclusion. Yu and his colleagues
previously suggested that visfatin could promote fibroblast
proliferation and myocardial fibrosis in neonatal rat
cardiomyocytes in vitro [28]. It has also been reported
that myocardial fibrosis promotes various conduction
abnormalities and causes malignant VA to occur [2932]. Furthermore, considering its key role in unstable

plaques, higher circulating visfatin concentrations have
been observed in patients with slow coronary flow [33],
which contributes to malignant VA. Notably, visfatin levels
also differed statistically between patients with benign
VA and control patients without SHD. This is eventually
traced to the fact that heart structural disorders were not
absolutely necessary for VA to induce visfatin elevation
in these individuals, though the mechanism remains
undiscovered. On that basis, elevated serum levels of
visfatin show a specific predictive value for the occurrence
of VA regardless of SHD, and the risk of VA increases with
the serum visfatin concentration.
This study has some limitations. Firstly, the population
size is small, and all our knowledge of causal relations
comes from the cross-sectional study. Due to this size
limit, we cannot confirm whether the knowledge might
accord with the law of fact. Secondly, our classification of
VA is mainly based on 24-h Holter monitoring rather than
electrophysiological examination, which leads to an error
between the theoretical VA grouping results and the actual
results. Another limitation of this study is that visfatin
concentration was assessed only once and repeated during
the hospitalization period. As serological results of visfatin
are not reviewed regularly, a long-term follow-up of the
development of VA is still necessary. On all accounts, the
utility of visfatin assessment for VA screening requires
further study.
5. Conclusion
The serum level of visfatin is significantly increased in
patients with VA regardless of the presence of the SHD.
Furthermore, it is also a good biomarker for the risk
stratification of VA.
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